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INTRODUCTION: Serous carcinomas are the most frequent histologic type of ovarian and peritoneal cancers, and can
also be detected in the endometrium and fallopian tubes. Serous carcinomas are usually high-grade neoplasms
when diagnosed, yet the identification of an associated precursor lesion remains challenging. Pathological
examination of specimens obtained from prophylactic bilateral salpingo-oophorectomies that were performed for
patients harboring BRCA1/2 mutations suggests that high-grade serous carcinomas may arise in the fallopian tubes
rather than in the ovaries.
OBJECTIVE: To investigate the presence and extent of fallopian tube involvement in cases of serous pelvic
carcinomas.
METHODS: Thirty-four cases of serous pelvic carcinoma with clinical presentations suggesting an ovarian origin were
analyzed retrospectively. Histologic samples of fallopian tube tissues were available for these cases and were
analyzed. Probable primary site, type of tubal involvement, tissues involved in the neoplasia and vascular
involvement were evaluated.
RESULTS: Fallopian tube involvement was observed in 24/34 (70.6%) cases. In 4 (11.8%) of these cases, an
intraepithelial neoplasia was present, and therefore these cases were hypothesized to be primary from fallopian
tubes. For an additional 7/34 (20.6%) cases, a fallopian tube origin was considered a possible primary.
CONCLUSIONS: Fallopian tubes can be the primary site for a subset of pelvic high-grade serous carcinomas.
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INTRODUCTION
Ovarian cancer is the eighth most common malignancy
diagnosed in women, the fifth leading cause of death from
cancer in women and the leading cause of death among
gynecologic cancers. Approximately 75% of all ovarian
cancer cases are in an advanced stage at the time of
diagnosis. Furthermore, the median overall survival period
for advanced ovarian cancer is 15–23 months, with a 5-year
survival rate of only 20%.1,2 Unfortunately, there are no
effective prevention or screening programs currently in
place that have been shown to improve patient survival for
this disease.
For most women, the lifetime risk of developing ovarian
cancer is ,1.7%. However, for women carrying BRCA1 or
BRCA2 gene mutations, that risk increases to 56% and 27%
respectively.3 Therefore, the need for prevention and
screening programs is even more significant for this
population of women.
The most frequent histologic type diagnosed for ovarian
cancers is serous carcinoma, which corresponds to ,80% of
ovarian cancer cases in developed countries.4 Serous
carcinomas are classified as low grade or high grade,5–7
and develop from two different pathogenetic path-
ways.7,8,13–15 Low-grade serous carcinomas harbor muta-
tions in k-ras and braf,7–13 whereas high-grade serous
carcinomas present mutations in the TP53 gene.11,12
One of the significant aspects of ovarian carcinogenesis
that remains unclear is the precursor lesion responsible for
this disease. For almost all epithelial gynecological cancers,
whether they arise from the vulva, vagina, cervix or
endometrium, they arise via a sequence of events that
begins in normal epithelium, then passes through non-
obligatory precursor lesions to become invasive neoplasias.
For ovarian cancer, as it is usually diagnosed in its advanced
stages, ovarian precursor lesions have not been identified.
However, in the last few years, increasing evidence has
indicated that tubal fimbria lesions are candidates to be
Copyright  2011 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2011;66(1):73-76 DOI:10.1590/S1807-59322011000100013
73
precursor lesions of ovarian high-grade serous carcino-
mas.14
Studies of surgical specimens derived from prophylactic
salpingo-oophorectomies performed on women carrying
BRCA gene mutations have been associated with a 2.3% rate
of occult carcinomas. In almost all cases, the neoplasias
involved the fallopian tubes instead of the ovaries, and
intraepithelial tubal neoplasias were present in the fimbria
region. When the end of the terminal fimbriae were
systematically processed and examined, the incidence of
fimbrial intraepithelial neoplasias increased to as much as
17%.15
Surprisingly, most of the cancers detected in their early
stages in women carrying BRCA mutations arise in the
fallopian tube. Additional studies have further pinpointed
the distal fimbrial portion of the fallopian tube as the most
common site of origin.15–17 However, other studies have
found a high frequency of early-stage cancer in the fimbriae
of women who do not carry BRCA mutations, yet have been
diagnosed with ovarian and peritoneal serous carcinomas.
In combination, these results suggest that a significant
proportion of serous carcinomas have a fimbrial origin,
independent of BRCA mutations.17,18
Based on the uncertain identity of the precursor lesions
associated with ovarian serous carcinomas, and the hypoth-
esis that the fallopian tubes are the primary site of these
malignancies, this retrospective study was conducted to
evaluate the frequency and patterns of involvement of the
uterine tubes in a cohort of high-grade pelvic serous
carcinomas.
MATERIAL AND METHODS
This study was approved by the Department of Obstetrics
and Gynecology and by the Department of Pathology
scientific committees of the Faculdade de Medicina da
Universidade de Sa˜o Paulo (Brazil), as well as by the ethics
committee for research projects of the Hospital das Clinical
da Faculdade de Medicina da Universidade de Sa˜o Paulo
(Brazil) (Comissa˜o de E´tica para Ana´lise de Pesquisa –
CAPPesq) (under no. 0283/09).
This retrospective study included 34 consecutive cases of
patients presenting with pelvic tumors that were clinically
suspicious for an ovarian origin. These cases were diag-
nosed between January 1, 2005 and July 1, 2010, and were
processed and diagnosed by the same pathologist (FMC).
Only cases with at least three histological sections of
fallopian tube tissue, with representative areas of fimbriae,
were analyzed. Furthermore, all cases were classified
according to: (a) primary tumor site; (b) fallopian tube
involvement; (c) involvement of other organs; and (d)
lymphatic vascular involvement.
To define the primary tumor site, the following char-
acteristics were evaluated: tumor volume, distribution of
tumor in the ovaries (diffuse or partial) and the presence of
intraepithelial carcinoma (for tubal and endometrial ori-
gins). Partial involvement of ovaries was associated with
larger tumors in the peritoneum, and these were considered
to be peritoneal in origin. Diffuse involvement of the ovaries
was also suggestive of an ovarian origin. The presence of
intraepithelial serous carcinoma in the fallopian tubes
was indicative of a tubal origin. Endometrial origin was
considered in cases with an in situ component associated
with the endometrium and minimal to absent ovarian
involvement. Cases involving multiple organs without a
clear site of origin were classified as having an indetermi-
nate site.
Tubal involvement was accessed in all cases and, when it
was present, it was classified as: intraepithelial neoplasia,
serosa involvement, intraluminal neoplasia (not connected
to the mucosa) or wall invasion.
RESULTS
For the 34 cases examined, patient age ranged from 24 to
68 years, with a median age of 51 years and a mean age of
52.3¡11.32 years. The main surgical–pathological findings
are listed in Table 1, and ovarian involvement was
frequently observed (91.2%). However, in 12/31 (38.7%)
cases, the ovarian parenchyma was partially involved, with
neoplasias only detected on the surface and the superficial
cortical stroma. The largest tumor among these cases was
Table 1 - Surgical and pathological findings in 34 pelvic serous carcinoma cases.
Surgical-pathological features N (%)
Surgical procedure Complete staging* with lymph node samples 16 (47%)
Complete staging without lymph node samples 11 (32.3%)
Hysterectomy with bilateral salpingo-oophorectomy 2 (5.9%)
Bilateral salpingo-oophorectomy 3 (8.8%)
Unilateral salpingo-oophorectomy with peritoneal biopsy 1 (2.9%)
Salpingectomy with peritoneal biopsy 1 (2.9%)
Ovarian involvement Absent 2 (5.9%)
Bilateral, partial involvement 10 (29.4%)
Bilateral, diffuse involvement 17 (50%)
Unilateral, partial involvement 2 (5.9%)
Unilateral, partial involvement 2 (5.9%)
Unknown{ 1 (2.9%)
Peritoneal involvement Absent 4 (11.8%)
Present 30 (88.2%)
Vascular embolization Absent 19 (55.9%)
Present 15 (44.1%)
Lymph node metastasis{ Absent 12 (75%)
Present 4 (25%)
*Total hysterectomy with bilateral salpingo-oophorectomy, omentectomy and multiple peritoneal biopsy.
{Patient submitted to unilateral salpingectomy.
{Available for 16 cases.
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1.1 cm along its greatest diameter, and bilateral involvement
was more frequent than unilateral involvement (27/31,
87.1% vs. 4/31, 12.9% respectively).
Peritumoral neoplastic vascular involvement was
observed in 15/34 (44.1%) cases. Moreover, 2 (13.3%) of
these cases involved lymph node metastasis, 5 (33.3%) cases
had negative lymph nodes and, in 8 (53.3%) cases, the
lymph nodes were not examined. The 8 cases without
lymph node samples available were endometrial carcinoma
associated with peritoneal carcinomatosis (n = 2), ovarian
carcinoma (n= 3), tubal carcinoma (n= 2) and peritoneal
carcinoma (n= 1). Lymph node metastasis was also detected
in 2 cases without vascular neoplastic embolization, and
both were associated with primary tumors in the perito-
neum without tubal involvement.
The distribution of cases according to primary tumor site
and tubal involvement is presented in Table 2. Fallopian
tube involvement was identified in 24/34 (70.6%) cases, and
tubal serosa was involved in 23/24 cases. Furthermore, in
4/24 (16.7%) cases, the intraepithelial serous carcinoma
could be identified (Figure 1). For the other 20 cases, serous
neoplasia was associated with infiltration of the fallopian
tube wall (n = 17), exclusive serous involvement (n = 2) and
intraluminal neoplasia without an observable connection to
the tubal wall (n = 1). In addition, there were 2 cases where
the origin of the neoplasia was clearly localized to the
fimbriae and, in 4 cases, the intraepithelial neoplasia
characterized the origin in the fallopian tube. Seven other
cases had tubal involvement associated with either the
peritoneum (n=5) or the ovary plus the peritoneum (n= 2).
However, these cases were classified as indeterminate,
although there was a high probability that these neoplasias
were associated with a primary tubal tumor. Furthermore,
in 2 of these cases, involvement of the fimbriae region was
evident.
DISCUSSSION
High-grade serous carcinomas involving pelvic organs
are usually classified as ovarian carcinomas. Moreover, up
until the late 1990s, primary fallopian tube carcinoma was
considered one of the less common malignancies of the
female genital tract, representing less than 1% of all
gynecologic malignancies.19 Unfortunately, despite signifi-
cant efforts worldwide to improve the prevention, screening
and early diagnosis of ovarian cancer, little or no progress
has been made in improving patient survival. In the United
States, the estimated number of new ovarian cancer cases in
2010 is 21,880, while the number of anticipated deaths is
13,850.2 These high mortality rates require that efforts be
improved to reduce the risk of diagnosing ovarian cancer in
its advanced stages, particularly for women with BRCA
mutations. In the latter case, a bilateral salpingo-oophor-
ectomy at the age of 35–40 years, or when childbearing is
complete, is the strategy currently advocated to reduce the
risk of ovarian cancer in patients with BRCA mutations.20
However, emerging evidence indicates that the fallopian
tube origin of some high-grade ovarian serous carcinomas
may necessitate that the strategies for prevention and early
detection be modified further.14,16,21,22
The findings of this study were consistent with the
hypothesis that most pelvic high-grade serous carcinomas
have a fallopian tube origin that was previously more
commonly attributed to the ovaries. In this study, all the
cases examined had a preoperative diagnosis of a probable
ovarian carcinoma, and some were diagnosed pathologi-
cally as serous ovarian carcinomas. Furthermore, patholo-
gical examinations indicated that an ovarian neoplasia was
present in 31/34 cases. However, in 12 (39%) of these cases,
the ovarian involvement was partial, suggesting secondary
involvement.
Fallopian tube involvement was identified in more than
70% of the cases examined, and this is consistent with the
results of Kindelberger et al.23 Moreover, the fallopian tubes
were the clear primary site of origin in 4 (17%) of the cases
reviewed in the present study, which was confirmed by the
identification of an intraepithelial carcinoma present in
the fallopian tubes for each case. In another 7 (29.1%) cases,
the fallopian tubes were predicted to be the primary site.
Furthermore, in two of these cases, the tumor was closely
related to the fimbriae, which is the anatomic site of origin
for tubal carcinomas according to recent studies.14,15,17,23
Even among the cases classified as ovarian carcinomas,
fallopian tube involvement was very common (6/9, 66.7%),
thereby suggesting that primary fallopian tube neoplasia
may be involved. Correspondingly, it has previously been
hypothesized by Kurman and Shih7 that serous carcinomas
can originate in the fimbriae, then shed on to the peritoneal
or ovarian surfaces to grow and manifest clinically.
One of the limitations of this study was the small number
of cases examined. However, an additional limitation was
Table 2 - Summary of pathology data from 34 cases of
pelvic serous carcinoma.
Primary origin site N (%) Fallopian tube involvement
Peritoneum 11 (32.3%) 6 (54.5%)
Ovary 9 (26.5%) 6 (66.7%)
Fallopian tubes 4 (11.8%) 4 (100%)
Endometrium* 2 (5.9%) 0 (0)
Undetermined 8 (23.5%) 8 (100%){
Total 34 (100%) 24 (70.6%)
*Serous endometrial carcinoma with peritoneal involvement.
{In 7 of these cases, the fallopian tube was considered as the possible
primary site.
Figure 1 - Fimbria region of the fallopian tube showing abrupt
transition between mesothelial lining and intraepithelial neo-
plasia. Hematoxylin-eosin. Original magnification 1006.
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that not all the cases analyzed had the fimbriae region
included in its entirety for histological studies, as recom-
mended by the SEE-Fim (Sectioning and Extensively
Examining the FIMbria) protocol.15 If additional histological
sections of fimbriae had been available, it is possible that
more cases of primary tubal origin would have been
identified, especially as precursor lesions present in the
fimbriae, the so-called p53 signature, can be very tiny as a
nest of approximately 13 cells that express p53.24
Chronic inflammation has been shown to be a carcino-
genic factor for many sites, including the cervix, cardia and
liver. It has also been considered to be a possible factor in
the development of tubal carcinogenesis. 21,25 In addition,
the fallopian tube is a site that is regularly exposed to a
variety of inflammatory agents. For example, Chlamydia
trachomatis is a very common biologic agent that infects the
fallopian tubes. Although it is present as an asymptomatic
disease most of the time, the role of Chlamydia trachomatis in
fallopian tube carcinogenesis remains to be evaluated.25
As the fallopian tubes emerge as a potential site of origin
for some ovarian serous high-grade carcinomas, additional
aspects need to be considered. For example, what should be
the prophylactic surgery prescribed for high-risk women?
How should screening and early diagnosis strategies be
modified according to this new perspective? What are the
cofactors related to fimbriae carcinogenesis?
In conclusion, fallopian tubes were identified as a primary
site for a subset of pelvic serous carcinomas. Additional
studies of larger cohorts will be needed to confirm these
results. However, these initial studies provide valuable
insight into the identification of potential primary tumor
sites for ovarian carcinomas that have previously proved
elusive in many cases.
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